Abstract | Healthy kidneys maintain fluid and electrolyte homoeostasis by adjusting urine volume and composition according to physiological needs. The final urine composition is determined in the last tubular segment: the collecting duct. Water permeability in the collecting duct is regulated by arginine vasopressin (AVP). Secretion of AVP from the neurohypophysis is regulated by a complex signalling network that involves osmosensors, barosensors and volume sensors. AVP facilitates aquaporin (AQP)-mediated water reabsorption via activation of the vasopressin V2 receptor (AVPR2) in the collecting duct, thus enabling concentration of urine. In nephrogenic diabetes insipidus (NDI), inability of the kidneys to respond to AVP results in functional AQP deficiency. Consequently, affected patients have constant diuresis, resulting in large volumes of dilute urine. Primary forms of NDI result from mutations in the genes that encode the key proteins AVPR2 and AQP2, whereas secondary forms are associated with biochemical abnormalities, obstructive uropathy or the use of certain medications, particularly lithium. Treatment of the disease is informed by identification of the underlying cause. Here we review the clinical aspects and diagnosis of NDI, the various aetiologies, current treatment options and potential future developments.
Introduction
Nephrogenic diabetes insipidus (NDI) results from failure of the kidneys to concentrate urine. Patients with this disease typically produce around 12 l of urine per day. Assuming a bladder volume of 500 ml, this volume of urine will necessitate voiding approximately once per hour throughout the day and night. Moreover urinary fluid losses need to be replenished by constant fluid intake. The disease has a substantial impact on quality of life as sleep is frequently interrupted and patients must plan their daily activities with logistics for frequent voiding and access to drinking water.
Primary and secondary forms of NDI exist. Paedi atricians typically see patients with primary inherited forms of the disease, mostly boys, presenting in the first year of life with failuretothrive and vomiting. By con trast, in adults acquired NDI is much more common than primary NDI. Medical treatment can ameliorate the symptoms of NDI and as understanding of the under lying pathophysiology improves, new potential treatment options arise. In this Review we consider the clinical, diagnostic and therapeutic aspects of NDI in the context of the physiology of renal water handling to enable a molecular understanding of the disease. We also discuss recent insights into the regulation of water permeability and their consequences with respect to diagnosis and new treatment options.
Physiology of urine concentration
Healthy adult kidneys produce approximately 180 l of primary glomerular filtrate per day. 1 The vast major ity of this filtrate is reabsorbed in the proximal tubule, which is freely permeable to water owing to the consti tutive expression of aquaporin1 (AQP1) water chan nels. 2 As solutes are reabsorbed in the proximal tubule, water follows passively along the osmotic gradient. The remaining urine is thus still isotonic when it enters the loop of Henle, the key segment for countercurrent con centration ( Figure 1 ). Urine concentration begins in the thin descending limb (TDL). Mechanisms of concentra tion include AQP1mediated exit of water into the med ullary interstitium. 3 However, data from several rodent models show that Aqp1 expression is mainly restricted to the first 60% of the TDL rather than the deeper papillary parts in which the steepest part of the osmotic gradi ent is generated. 4 Concentration of the tubular fluid in these innermost parts of the TDL might occur via passive sodium influx, 5 but no substantial sodium permeabil ity has been observed. 6 Thus, the exact mechanism of urinary concentration in the innermost part of the medulla remains to be elucidated.
Urine subsequently enters the thick ascending limb (TAL, also known as the diluting segment), which is impermeable to water but actively removes sodium chloride via the cotransporter solute carrier family 12 member 1 (SLC12A1, also known as NKCC2), thereby diluting the urine. 7 The accumulation of solutes in the interstitium generates the driving force for the removal of water from the TDL (in longlooped nephrons) and the entry of sodium chloride (in shortlooped nephrons), completing the countercurrent multiplier.
Further removal of sodium chloride occurs in the distal convoluted tubule via SLC12A3 (also known as NCC). At entry into the arginine vasopressin (AVP)sensitive con necting tubules and collecting ducts, urine osmolality is typically around 50-100 mOsm/kg. The final osmolality of the urine is solely dependent on the availability of water channels. If these channels are present, water exits the tubule following the interstitial concentration gradient and the urine is concentrated. If no water channels are present dilute urine will be excreted.
Vasopressin-regulated water permeability
Vasopressin secreted by hypothalamic neurons in response to changes in soma volume is the key regulator of the water permeability of the collecting ducts ( Figure 2 ). The key cell type that mediates this regulated water permeability is the principal cell, which constitutively expresses AQP3 and AQP4 on the basolateral side. 2 The water permeability of the apical membranes of the prin cipal cell is determined by the availability of AQP2 water channels. In the absence of AVP signalling, these channels are located in intracellular vesicles and no apical water permeability exists. 8 Binding of AVP to the vasopres sin V2 receptor (AVPR2) initiates a signalling cascade that ultimately leads to the insertion of AQP2 channels into the apical membrane ( Figure 3 ). AVPR2 is a Gprotein coupled receptor and binding of AVP leads to the release of stimulatory Gprotein, which in turn activates the neighbouring adenylyl cyclase. 9 The resulting increase in levels of cAMP activates protein kinase A (PKA).
The cytoplasmic carboxyterminal tail of AQP2 has five canonical PKA phosphorylation sites: Thr244, Ser256, Ser261, Ser264 and Thr269 (Ser269 in mice). 10 Upon administration of the vasopressin analogue 1 desamino8Darginine vasopressin (DDAVP), phos phorylation of AQP2 at Ser256, Ser264 and Ser269 is abundantly increased, whereas phosphorylation at Ser261 is decreased; 10 specific phosphorylation of these residues might serve distinct physiological roles. In a mammalian cell line (LLCPK1) transiently transfected with AQP2, phosphorylation at Ser256 was essential for trafficking of the water channel to the plasma mem brane, 11 whereas in Xenopus oocytes, phosphorylation of at least three subunits of the AQP2 tetramer at Ser256
Key points ■ Nephrogenic diabetes insipidus (NDI) is caused by inability of the kidneys to concentrate urine by reabsorbing water in the collecting duct ■ NDI can be inherited (X-linked or autosomal) or acquired, most commonly as a result of lithium treatment ■ Management of primary forms of NDI focuses on dietary modification to reduce osmotic load and pharmacological treatment with inhibitors of prostaglandin synthesis and thiazide diuretics ■ With appropriate treatment, complications of NDI-such as failure to thrive and mental retardation resulting from repeated hypernatraemic dehydration-can be avoided ■ New treatment approaches for congenital NDI have been tested in animal models, but efficacy in patients has not yet been confirmed was required for redistribution from storage vesicles to the apical plasma membrane. 12 The critical role of Ser256 in AQP2 function was confirmed by the identification of mutations that impair phosphorylation at this site in patients with NDI. 13, 14 In vitro studies demonstrated the failure of such mutants to reach the apical membrane. 13, 14 AVP also induces phosphorylation of AQP2 at Ser269, but this action is delayed and requires prior phosphory lation at Ser265. 15 Phosphorylation at Ser269 might increase retention of AQP2 at the apical plasma mem brane and interactions of AQP2 with proteins partici pating in the endocytic machinery. 16 By contrast, AQP2 phosphorylated at Ser261 is found mainly in intracellular vesicles; phosphorylation at this site is thought to stabi lize ubiquitination of AQP2 17 at Lys270. 18 Ubiquitination might, therefore, mediate the endocytosis of AQP2 from the plasma membrane in the absence of AVP stimula tion. This mechanism leads to a limited tenure of AQP2 in the apical membrane of principal cells; endocytosis of this water channel enables the cells to return to their waterimpermeable state ( Figure 3 ). The role of AQP2 phosphorylation at Thr244 is unknown.
The actions of cAMP might not only be mediated via the classical PKA/cAMPdependent protein kinase pathway, but also by guanine nucleotideexchange factors such as exchange protein directly activated by cAMP (Epac). 19 Like PKA, Epac contains an evolutionally con served cAMPbinding domain that senses intracellular cAMP levels and acts as a molecular switch to control diverse biological functions. 20 Epac might be involved in the longterm regulation of AQP2 abundance, whereas PKA has independent shortterm effects. 21 In addition to an acute role in AQP2 localization, AVP mediated increases in cAMP promote AQP2 expression via PKAmediated phosphorylation of the cAMP respon sive element binding protein, which subsequently stim ulates transcription from the AQP2 promoter. [22] [23] [24] The change in localization of AQP2 occurs within minutes, whereas the increase in transcription requires hours to take effect. 25, 26 
Congenital NDI
In 1992 the AVPR2 gene that encodes the AVP2 recep tor was cloned and mutations in this gene were identi fied in patients with Xlinked NDI (Figure 4) . [27] [28] [29] [30] The AQP2 gene was cloned in 1993 31, 32 and in 1994 mutations in AQP2 were found to underlie autosomal recessive NDI. 33 The discovery of these two key genes-AVPR2 and AQP2-has enabled genetic testing of affected patients. Mutations in either of these genes are identi fied in almost all patients with a clear clinical phenotype of congenital NDI. 34, 35 AVPR2 mutations Approximately 90% of patients with inherited NDI have a mutation in AVPR2. 36, 37 As this gene is located on the Xchromosome, AVPR2 mutations have an Xlinked pattern of inheritance; consequently the major ity of patients with NDI are male. Female patients with NDI due to AVPR2 mutations have occasionally been described. 34, 35, [38] [39] [40] [41] In one study, 16 of 64 (25%) female carriers of AVPR2 mutations showed polyuric symptoms and four of these patients (6%) were diagnosed with com plete NDI rather than the milder partial NDI phenotype described below. 34 Skewed Xinactivation is thought to cause symptoms in some female carriers of AVPR2 mutations, although these symptoms do not necessar ily correlate with the Xinactivation patterns observed in leucocytes. 42 Presumably, Xinactivation patterns can differ between tissues, so the pattern in leucocytes might not reflect that in the kidney. In our experience at Great Ormond Street Hospital, London, UK, two female relatives in 20 families with AVPR2 mutations were diag nosed with complete NDI (D. Bockenhauer & D. Bichet, unpublished work). One of these women was the index case in her family, but not all female carriers have been systematically investigated. Partial NDI symptoms were observed in two other female carriers in one family. 43 A few AVPR2 mutations have been identified recur rently owing to a founder effect. For example, the Hopewell mutation (Trp71X)-derived from an Ulster Scot immigrant who arrived in Halifax, Canada on the ship Hopewell in 1761-has been identified in >40 North American patients. 44, 45 Another recurrent mutation is the Cannon mutation (Leu312X), which is named after a large pedigree with ≥38 affected patients in Utah. 45 Most patients, however, have individual mutations; to date >250 different AVPR2 mutations have been described in >300 families. 46 Interestingly, most of these mutations are missense and, when assessed in vitro, seem to encode functional but misfolded receptors, which are retained and degraded in the endoplasmic reticulum (ER). Figure 1 | The renal concentration and dilution mechanism. The loop of Henle forms a counter-current multiplier system that concentrates the urine. Urine is isotonic when it enters the loop of Henle and hypotonic when it exits into the collecting duct. The concentration gradient generated in the loop of Henle is driven by the active reabsorption of NaCl in the thick ascending limb by the transporter solute carrier family 12 member 1. The mechanism of concentration in the thin descending limb is not completely resolved, but likely involves passive water efflux and/or NaCl influx. Final concentration of urine occurs in the collecting duct and depends on the availability of aquaporin 2 water channels. The approximate osmolalities of the tubular fluid (pink boxes) and interstitial fluid (green boxes) are indicated.
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AQP2 mutations
Approximately 10% of cases of congenital NDI are due to lossoffunction mutations in the AQP2 gene located on chromosome 12. 34, 45, 48 These mutations are typically inherited in an autosomal recessive fashion, although a few mutations have been described to cause autosomal dominant disease.
13,49-51 AQP2 is a homotetramer; four subunits assemble to form the water channel. Dominant mutations typically affect amino acids in the Cterminus, leading to aberrant trafficking; mutant AQP2 subunits are able to oligomerize with wildtype protein to form tetramers, but exert a dominantnegative effect on traf ficking of these assembled tetramers. 52 Interestingly, specific mutations direct AQP2 trafficking to distinct cellular compartments, such as the Golgi complex, 13 late endosomes and lysosomes 49 or the basolateral membrane. 51, 53 These findings provide insights into the intracellular trafficking motifs of AQP2.
Epidemiology Few populationbased data on the incidence of congenital NDI exist, but estimates can be made. In 2000 we assumed that we had complete ascertainment of all the patients with AVPR2 mutations who were born in the province of Quebec, Canada between 1988 and 1997. 35 Indeed, in the subsequent 18 years, no patients with AVPR2 mutations born in the province during this period have emerged. Based on these data, we estimated the incidence of Xlinked NDI in the general population of Quebec to be four in 454,629 or approximately 8.8 per million (SD 4.4 per million) male live births. This estimate might be repre sentative of the general world population. However, owing to chance population genetic events, such as a founder effect, the incidence of NDI is elevated in certain regions. For example, in the Canadian maritime provinces of Nova Scotia and New Brunswick, we estimate the incidence of the Hopewell mutation to be 58 per million male live Nature Reviews | Nephrology Binding of AVP to the AVPR2 receptor expressed on the basolateral side of the principal cell stimulates the release of GαS, which in turn activates adenylyl cyclase, resulting in increased cAMP production. PKA is activated by cAMP and phosphorylates several residues in the C-terminus of AQP2. This phosphorylation enables trafficking of AQP2 to the apical membrane and the formation of AQP2 water channels. AQP2 is constantly retrieved from the membrane by endocytosis, so that ongoing water permeability depends on delivery of AQP2 to the membrane, either by recycling or generation of new channels. Water diffuses via these channels along the concentration gradient from the tubular lumen into the principal cell and exits into the interstitium via the constitutively expressed AQP3 and AQP4 water channels. In addition to PKA-mediated phosphorylation of AQP2, cAMP enhances transcription of AQP2. Some of the changes induced by cAMP are likely mediated by EPAC. The G-protein coupled receptors EP2, EP4 and the secretin receptor are also expressed in principal cells. Targeting of these receptors could potentially be used to stimulate membrane insertion of AQP2 in the absence of functional AVPR2. Abbreviations: AQP, aquaporin; AVP, arginine vasopressin; AVPR2, vasopressin V2 receptor; CREB, cAMP responsive element binding protein; EP2, prostaglandin E2 receptor EP2 subtype; EP4, prostaglandin E2 receptor EP4 subtype; EPAC, exchange protein directly activated by cAMP; G, G protein; PKA, protein kinase A. births. 35 A higher incidence of NDI is also found in Utah due to the prevalence of the Cannon mutation. 44 Based on the families referred to us for genetic testing, we estimate that the incidence of NDI secondary to AQP2 mutations is five to ten times lower than that of NDI sec ondary to AVPR2 mutations. The incidence of this type of congenital NDI might, however, be increased in popula tions with a high degree of consanguinity; we have found an overrepresentation of the Val71Met AQP2 allele in patients of Pakistani descent. 53 
Secondary inherited forms of NDI
In addition to primary forms of congenital NDI a few cases of secondary inherited NDI have been reported. 54, 55 These patients have Mendelian diseases that affect tubular function with NDI as a secondary complication. In some such patients the NDI symptoms dominate the clinical picture, leading to an initial misdiagnosis, with the true underlying cause of disease subsequently identi fied. 54, 56 Most of the primary diseases associated with secondary NDI, such as Bartter syndrome and apparent mineralocorticoid excess, are associated with hypokalaemia and hypercalciuria. These associations might provide clues as to the aetiology of NDI, as both hypokalaemia and hypercalciuria are associated with decreased AQP2 expression. 57, 58 Hypercalciuria has been suggested to cause a urinary concentration defect medi ated by the calciumsensing receptor, which is expressed on the luminal side of collecting duct cells and is thought to affect AQP2 trafficking by altering cAMP levels. 59, 60 Acquired NDI
The majority of adults who present with NDI have acquired this disease, with lithium treatment being the predominant cause. [61] [62] [63] Reports of NDI among patients treated with lithium vary widely, but the incidence of this adverse effect has been reported to be as high as 85%. 62, 64 As 0.25-0.77% of the general population aged >65 years are prescribed lithium, it is not surprising that lithiuminduced NDI is fairly common. 65, 66 Indications for lithium treatment include bipolar disorder, schizo affective disorder, depression, alcoholism and cluster headaches. 63 Cessation of lithium therapy can resolve the symptoms of NDI, but this approach is not an option in most cases because the beneficial effects of the drug on the psychiatric disorder outweighs the negative impact of the polyuric complications on quality of life.
In rats, chronic lithium administration (>4 weeks) led to epithelial remodelling in the collecting duct and a dramatic reduction in the number of principal cells. 67 Moreover, in the mouse collecting duct cell line mpkCCD, lithium exposure decreased Aqp2 abundance inde pendent of cAMP levels. 68 Consistent with these data, decreased urinary excretion of AQP2 has been observed in patients with lithiuminduced NDI. 69 The exact mecha nism of lithium toxicity on the principal cell remains to be elucidated, but robust data suggest that lithium exerts its effect after entering the cell through epithelial sodium channels (ENaCs), which have a high permeability for lithium. 10 Consequently, treatment with ENaC block ers, such as amiloride, can increase urine osmolality and ameliorate polyuria in lithiuminduced NDI. [70] [71] [72] Other acquired causes of typically transient NDI include hypercalcaemia, hypercalciuria and obstructive uropathy. In patients with obstructive uropathy, NDI is thought to result from direct suppression of AQP2 expres sion, which might be mediated by hydrostatic pressure. Animal studies have shown decreased Aqp2 expres sion in the setting of bilateral ureteric obstruction, 73 whereas in unilateral obstruction a marked decrease in Aqp2 is seen only in the obstructed kidney. 74 This down regulation of Aqp2 persists up to 30 days after release of obstruction, perhaps explaining the diuresis often observed after release of severe obstruction in patients. 9 
Initial presentation
Most patients with congenital NDI present with failure to thrive during the first few months of life, whereas those The Nobel Prize in chemistry is awarded to du Vigneaud for the synthesis of AVP AVPR2 is cloned and mutations in this gene are identi ed in patients with X-linked nephrogenic diabetes insipidus [27] [28] [29] [30] AQP2 is cloned 31, 32 Mutations in AQP2 are found to underlie autosomal-recessive nephrogenic diabetes insipidus with acquired NDI typically present later in life with poly uria and/or polydipsia. In patients with congenital NDI the antenatal history is typically normal with no polyhydram nios, which helps to distinguish NDI from other polyuric disorders, such as Bartter syndrome. Parents often report that the baby sucks vigorously but vomits shortly after wards. This vomiting is thought to occur because intake of large fluid volumes causes gastrooesophageal reflux. NDI is a rare disease so does not feature promi nently on the diagnostic radar of frontline medical staff. Families seeking medical attention for their undiagnosed baby might, therefore, be sent home without further investigations because the attending professionals are falsely reassured by the large urine output. Laboratory investigations in such instances would show the typical picture of hypernatraemia with inappropriately dilute urine, the biochemical fingerprint of diabetes insipi dus. If blood tests are obtained and hypernatraemia is noted without consideration of a urinary concentration defect, inappropriate treatment with 0.9% saline might be instigated because of concerns that correction of hyper natraemia might otherwise be too rapid. Unfortunately, given the imbalance between the sodium concentration of the administered fluid (154 mmol/l) and the urine (usually <10 mmol/l), this approach will result in even higher plasma sodium concentrations.
Diagnosis
In patients who present with hypernatraemic dehydra tion and dilute urine, a DDAVP test can help to dis tinguish between cranial diabetes insipidus (which is normally the result of disease of the hypothalamus or surrounding tissues) and NDI. In patients with suspected diabetes insipidus who present with polyuria and normal plasma biochemistries, a water deprivation test might first be performed to challenge urinary concentration.
DDAVP test
As DDAVP has high specificity for AVPR2 it can be used to assess the renal response whilst avoiding AVPR1 mediated vasoconstriction. DDAVP is available in for mulations suitable for oral, intranasal, subcutaneous or intravenous administration. After DDAVP administra tion a urine osmolality >800 mOsm/kg is usually consid ered normal and excludes a diagnosis of NDI, whereas a urine osmolality below plasma osmolality indicates AQP2 deficiency and is consistent with the diagnosis. Care needs to be taken in the interpretation of inter mediate results, especially in infants, as full urinary concentrating ability develops during the first year of life. 75 Other causes for submaximal values include interstitial renal disease, use of loop diuretics, partial NDI, washout of the interstitial med ullary concentration gradient or technical failure of the test, for example as a result of incomplete DDAVP absorption.
Various protocols for the DDAVP test exist, but we prefer to use intravenous administration to enable the most reliable absorption of the polypeptide. 76 The DDAVP dose (0.3 mcg/kg) used in this test is the same as that used to boost factor VIII concentration in patients with mild haemophilia or von Willebrand disease. 77 , 78 The key risk of the test is the development of hypo natraemia in patients who respond to DDAVP and keep drinking. The physiological suppression of thirst from reduced plasma osmolality prevents this complication in the vast majority of responders, but patients with habitual polydipsia and babies who keep receiving feeds from their carer are at risk. Strict observation of fluid balance is required to prevent this potentially serious complication and patients should only be allowed to receive a fluid volume equivalent to their ongoing losses. A key advantage of intravenous administration is the short halflife of DDAVP in blood, which necessitates an observation time of only 2 h, thus minimizing the burden of the test. Other advantages include a low risk of test failure owing to incomplete absorption and the ability to distinguish between Xlinked and autosomal recessive forms of NDI, as AVPR2 mediates haemodynamic and coagulation factor changes in response to high dose DDAVP. 76 This response is abrogated in patients with defective AVPR2 function, yet retained in those with mutations in AQP2. The low plasma levels of DDAVP achieved with other forms of administration make detection of these subtle changes virtually impossible.
Spectrum of clinical disease

Mental impairment
As with most inherited diseases a wide spectrum of sever ity of clinical disease is observed in NDI. The most severe consequences are seen in patients who have not received adequate treatment and have experienced repeated epi sodes of hypernatraemic dehydration, leading to brain damage and impaired mental development. 39, 79, 80 In some such patients intracranial calcifications can be observed. These calcifications are thought to result from endothe lial cell necrosis during severe dehydration and thus might represent a radiological correlate to brain damage from recurrent hyperosmolar stress associated with hypernatraemic dehydration. 81 Fortunately, cases of severe mental impairment in patients with NDI are now virtually nonexistent in coun tries where modern health care is available. Nevertheless, impaired school performance and behavioural abnor malities are often reported among patients with NDI. In a Dutch study, eight of 17 patients with NDI were diag nosed with attention deficit hyperactivity disorder. 82 This diagnosis might be partly related to the constant craving for water and need to void. Some data, however, suggest that behavioural abnormalities might be an intrinsic aspect of the disease. Vasopressin (and oxytocin) act as neurotransmitters that modulate the autonomic fear response 83 and vasopressin has been described to enhance aggression, anxiety and stress levels in an animal model. 84 Raised vasopressin levels might also potentially affect longterm behaviour in patients with NDI.
Flow uropathy
Dilatation of the urinary tract is a recurrently noted com plication of NDI and patients with poor voiding habits are especially at risk. 39, 85, 86 In those with hydronephrosis, anatomic causes of obstruction should also be considered.
Such obstructions are potentially remediable and even minor impediments to urine flow can cause severe dilata tion in this polyuric disorder. 87 Obstructive nephropathy can be seen in cranial diabetes insipidus and NDI, and if untreated can lead to obstructive endstage renal disease.
Partial NDI Some patients with congenital NDI have a mild pheno type; they present after infancy with normal develop ment, often for the assessment of polyuria or enuresis, and typically show intermediate urine osmolality after DDAVP administration (greater than plasma osmolal ity but <800 mOsm/kg). Patients with partial NDI typi cally carry mutations that result in partial function of either AVPR2 43, 88 or AQP2. 89, 90 The first mutation to be associated with partial NDI was the Asp85Asn mutation in AVPR2. 88 Interestingly, another missense mutation, Val88Met, has been associated with partial NDI in some patients and complete NDI in others. 43, 91, 92 The under lying disease mechanism in patients with these missense mutations is ER retention of the mutant protein, but the degree to which the mutant protein can escape from this retention and traffic to the cell membrane seems to differ between individual patients.
Treatment
Current treatment approaches for congenital NDI focus on ameliorating the symptoms rather than curing the disease. If possible, treatment of acquired NDI should target the underlying cause, such as relief of urinary obstruction or amiloride therapy in lithiumassociated NDI. 72 If such approaches are not possible, treatment of congenital NDI is comparable to that of primary NDI.
Management of hypernatraemic dehydration
Most emergency protocols for any patient with hyper natraemic dehydration suggest initial treatment with 0.9% saline, owing to concerns about lowering plasma sodium levels too rapidly. The situation differs, however, in patients with NDI because of the ongoing losses of essentially pure water with the urine; infusion of 0.9% saline will result in excess sodium chloride administration and thus worsen the hypernatraemia. In these patients, isotonic fluids should be reserved only for acute intravas cular volume expansion in hypovolaemic shock, which is an exceedingly rare complication, as extracellular fluid volume is usually sufficiently preserved in hypernatrae mia. Thus, patients with NDI should be treated with hypotonic fluids, either enterally (using water or milk) or if necessary intravenously (using 5% dextrose in water). Hypotonic fluids must never be administered as an intra venous bolus; instead, the infusion rate should only slightly exceed the urine output. The aim is to provide just enough water to safely normalize plasma sodium concentration at a rate of <0.5 mmol/l per h (<10-12 mmol/l per day). The main risk of a rapid decrease in plasma sodium is cerebral oedema and potentially death. [93] [94] [95] [96] Consequently, careful fluid balance and frequent monitoring of clinical state and biochemistries is key to safe treatment and requires a clini cal environment with sufficient experience in the treat ment of complicated electrolyte disorders. Fluids should be taken orally as soon as feasible, to enable the thirst physiology to properly regulate fluid intake. As dextrose in water provides no osmotic load (Box 1), urine output can decrease substantially, highlighting the importance of ongoing monitoring and fluid balance to avoid rapid swings in plasma sodium concentrations.
Diet
Dieticians have a key role in the management of patients with NDI, especially in the first year of life when intake of fluid and calories is coupled. Minimizing the osmotic load (Box 1), whilst providing the recommended caloric and protein intake to enable normal growth and development is a cornerstone of paediatric NDI management.
Thiazide diuretics
The use of diuretics in polyuric disorders seems counter intuitive. The therapeutic potential of these agents in NDI was discovered more or less serendipitously, but reported in patients as early as 1905. 97 This observa tion was confirmed in the 1950s when administration of hydrochlorothiazide was shown to reduce urine output in experimental animals with diabetes insipidus by as much as 50%. 98 An early study in patients with NDI showed a small reduction in urine volume with concomitant increases in urine osmolality and sodium shortly after commencing hydrochlorothiazide treatment. 99 After 3 days of treatment, sodium excretion had decreased to less than baseline, whereas urine output had decreased to ~50% of baseline. These changes were associated with reductions in plasma volume and body weight. The researchers astutely concluded that the initial increase in urine osmolality was related to inhibition of urinary dilu tion, mediated by decreased salt reabsorption through the thiazidesensitive cotransporter SLC12A3 in the distal tubule, and that the loss of sodium led to a reduction in plasma volume with subsequent enhanced proximal reab sorption of the glomerular filtrate, so that less water was presented to the collecting duct and lost in the urine.
A SLC12A3independent mechanism of thiazide mediated reductions in urine output was proposed based on studies in Slc12a3 knockout mice with lithiuminduced
The osmotic load consists of osmotically active substances that need to be excreted in the urine. The key contributors to the osmotic load are proteins, which are metabolized to urea (approximately 4 mmol per g of protein) and salts. A typical western diet contains about 800 m0sm per day. An individual with a urine osmolality of 800 m0sm/kg only needs 1 l of water to excrete this osmotic load, whereas a patient with maximal urine osmolality of 100 m0sm/kg will need at least 8 l of water for excretion. 1 g of table salt provides an osmolar load of ~36 mOsm (18 mOsm Na and 18 mOsm Cl). Consequently, in a patient with a urine osmolality of 100 mOsm/kg, each gram of salt ingested will increase the obligatory urine output by 360 ml. The osmolar load of a diet can be roughly estimated by multiplying the millimolar amounts of sodium and potassium by two (to account for the accompanying anions) and adding the amount of protein in grams multiplied by four. 132 As metabolism of lipids and sugars does not produce byproducts that require renal excretion, they do not contribute to the osmotic load. Diet is the key contributor to the osmotic load, but metabolism of own proteins during catabolic states also generate urea.
NDI. 100 A marked reduction in urine volume with unchanged urine osmolality was observed in these mice after hydrochlorothiazide administration. The research ers speculated that this reduction might be mediated by inhibition of carbonic anhydrase in the proximal tubule, resulting in reduced proximal sodium uptake and consequently-via tubuloglomerular feedbackdecreased glomerular filtration. They also found that in mpkCCD cells treated with lithium, hydrochlorothiazide administration led to an increase in Aqp2 abundance at the apical membrane. 100 However, the finding that lithium treated and control SLC12A3 knockout mice had similar urine osmolality after hydrochlorothiazide administration suggests that this effect is negligible in vivo.
The hypothesis of impaired proximal sodium reab sorption as a mechanism for reduced urine volume in NDI 100 is surprising and in direct contrast to the earlier hypothesis that enhanced proximal sodium uptake leads to enhanced proximal water reabsorption. 99 The degree to which these apparently opposing mechanisms occur in patients remains to be determined.
Prostaglandin synthesis inhibitors
An effect of prostaglandins on epithelial water perme ability was noted soon after their discovery. 101 With the advent of inhibitors of prostaglandin synthesis, such as indomethacin, experiments showed a synergistic effect of these new drugs with AVP. 102 An early study in an animal model of diabetes insipidus demonstrated that indo methacin reduced water diuresis independent of AVP. 103 A similar effect of prostaglandin synthesis inhibitors was noted in patients with NDI. [104] [105] [106] [107] Inhibitors of prostaglandin synthesis have become essential components in the treatment of NDI, particu larly in the first years of life when management is the most complicated. The effect of these drugs can be quite marked when first initiated. Indeed, hyponatraemic seiz ures associated with rapid lowering of plasma sodium levels as a result of commencing indomethacin and hydrochlorothiazide have been reported. 108 In our experi ence, urine osmolality is unchanged after indometha cin treatment, suggesting that the drug acts mainly by enhancing the proximal reabsorption of salt and water. 109 
Future outlook
Gene discovery Since the discovery of the two known NDI disease genes, AVPR2 [27] [28] [29] [30] and AQP2, 31, 32 in the 1990s, no additional causative genes have been reported. Mutations in AVPR2 or AQP2 are not, however, found in all patients. Between 2003 and 2013, the Montreal laboratory performed genetic testing for NDI in 208 families and identified causative mutations in AQP2 in 18 families and in AVPR2 in 119 families (D. Bichet, unpublished work). In some of the samples, mutations in genes causing renal disorders with secondary forms of NDI, such as Bartter syndrome were found, whereas in others, the phenotype was not detailed enough to clearly establish a diagnosis of NDI. 55 In a Japanese study no mutations were identified in seven of 62 (11%) families with clinical NDI, 34 suggesting that genes other than AQP2 and AVPR2 might be involved. However the phenotypes of these patients were poorly described and not further investigated by the referring physicians. In our clinical experience very few patients with a con vincing NDI phenotype have no identified mutation. In the Great Ormond Street cohort, we have identified three such patients from two families (D. Bockenhauer, unpub lished work). The results of our linkage analyses in these families were, however, consistent with the presence of mutations in AVPR2 or AQP2. Thus, if additional NDI disease genes are identified, they are likely to be causative only in a small subset of patients.
Novel treatments
The promise of molecular medicine is that improved understanding of specific molecular defects in individual patients will lead to the development of targeted, rational treatments. 110 Unfortunately, progress has been slow at best. Although several novel treatment approaches for patients with congenital NDI have been suggested, little clinical data are available. These novel approaches focus on restoring AVP signalling upstream of AQP2 so are not applicable to patients with AQP2 mutations. Gene therapy is currently the only novel approach that might be suitable for patients with these mutations.
AVPR2 antagonists
A new treatment strategy for NDI focuses on the fact that most patients carry missense mutations in AVPR2 that result in misfolding of AVPR2 and its retention in the ER. 47 If proper folding is induced using a molecular chaperone, the mutant receptor can escape the ER, traffic to the cell membrane and provide normal AVP signalling. Cellpermeable AVPR2 antagonists are molecular chaper ones that fit into the AVP binding pocket of AVPR2 and induce proper folding of the receptor. In patients with suitable mutations, these antagonists might provide a new treatment approach for NDI. The problem with this strategy is that the tighter the AVPR2 antagonists fit into the binding pocket, the better they promote surface expression of the receptor, but the less likely they are to diffuse off the receptor and enable normal AVP signal ling. Conversely, compounds with low affinity for AVPR2 are less efficient at promoting surface expression, but are more likely to diffuse off the receptors that traffic to the cell surface. Antagonists with intermediate affinity have the best overall efficacy, but one such agent, the orally active, nonpeptide AVPR1A antagonist SR49059, only moderately reduced urine volume in five patients with Xlinked NDI.
111 SR49059 is no longer provided by the pharmaceutical company because of the risk of idiosyn cratic increases in liver enzymes (these increases were not observed in patients with NDI who received the drug) and no further clinical data on this treatment approach have been published.
AVPR2 agonists
Cellpermeable agonists that stimulate AVPR2 independ ent of AVP are another potential treatment approach for patients with NDI. As these agents do not block AVPR2 signalling they could potentially be a more effective treat ment approach than AVPR2 antagonists. Unfortunately little interest in developing these agents seems to exist and they have not yet been tested in animal models.
Vasopressin analogues
A mutationspecific treatment strategy has also been suggested for patients with the Asn321Lys mutation in AVPR2. 112 The mutant receptor seems to have normal cell surface expression in vitro, but severely decreased affinity for vasopressin and DDAVP. AVP signalling via this receptor could reportedly be rescued using the vaso pressin analogue Val 4 desmopressin. Clinical data on the use of this compound in patients with NDI bearing this mutation have not yet been reported.
Prostaglandin receptor agonists
Another novel treatment approach for patients with AVPR2 mutations focuses on enhancing cAMP produc tion in the principal cells independent of AVPR2, for example via stimulation of prostaglandin E2 receptors coupled to adenylyl cyclase ( Figure 3) . Such a strategy would not benefit patients with the autosomal form of NDI, as AQP2 mutations result in a defect downstream of cAMP production.
In a mouse model of Xlinked diabetes insipidus with conditional deletion of the Avpr2 gene, administration of a prostaglandin E2 receptor EP4 subtype (EP4 recep tor) agonist resulted in an increase in urine concentra tion. 113 The peak increase in urine concentration (from 150 mOsm/kg to a maximum of 500 mOsm/kg) was short lived (3 h), possibly due to down regulation of EP4 recep tors in response to the high osmolality, but with mini pump constant infusions a sustained increase in urine osmolality from 200 mOsmol/kg to 300 mOsmol/kg was observed. Doubling of urine osmolality in patients with NDI would halve urine output (to ~6 l daily in adults) so would constitute successful treatment. In a rat model of NDI secondary to the administration of the AVPR2 antagonist, butaprost, an EP2 receptor agonist approxi mately doubled urine osmolality. 114 To date, no clinical data on the use of prostaglandinreceptor agonists in patients with NDI have been reported. Moreover, given the proven efficacy of prostaglandin synthesis inhibi tors in NDI treatment, doubts remain as to whether this approach would be a viable treatment option. 115 
Secretin receptor agonists
The secretin receptor is a Gprotein coupled receptor expressed in principal cells. Stimulation of this recep tor can increase cAMP levels. 116 Infusion of secretin and fluvastatin resulted in doubling in urine osmolality in mice with conditional deletion of the Avpr2 gene. 117 If appro priate scientific and ethical permission was obtained, shortterm therapy with a combination of secretin and fluvastatin could potentially be tested in humans with Xlinked NDI. Longterm secretin treatment might, however, be limited by adverse effects, such as flushing of the face and chest, vomiting, diarrhoea and fainting.
cGMP phosphodiesterase inhibitors
Increased levels of cyclic guanosine monophosphate (cGMP) have been shown to enhance trafficking of AQP2 to the luminal membrane and induce a shortlived increase in urine osmolality in Brattleboro rats (a model of cerebral diabetes insipidus with deficient vasopressin production by the hypothalamus). 118 This finding sug gests a potential role of cGMP phosphodiesterase inhibi tors, such as sildenafil, in the treatment of patients with NDI resulting from AVPR2 mutations.
Gene therapy
Genome editing of somatic tissue or embryos to correct mutant genes is a topic of considerable interest, but the ethics of these approaches-especially of embryo editingare controversial 119, 120 and no such treatment strategies have reached the clinic. We anticipate that the ethical governance, safety and longterm effects of editing thera pies could be determined within the next two decades. Patients with hereditary disorders, including NDI, might then benefit from these curative therapies.
Conclusions
Our understanding of the molecular physiology of urine concentration has advanced tremendously in the past 25 years. The study of patients with inherited NDI has identified AVPR2 and AQP2 as key proteins required for the regulation of water permeability in the collecting duct. Other tubular disorders, such as Bartter syndrome, can present with a secondary form of NDI, which might cause diagnostic confusion. In adult nephrology practice, the majority of patients with NDI have an acquired form of the disease owing to lithium treatment. Current treat ment of congenital NDI focuses on dietary modification, thiazides and inhibitors of prostaglandin synthesis. Novel therapies, such as mutationspecific treatment using molecular chaperones, have been investigated in animal models, but few data from clinical studies are currently available. The aim of these treatment approaches is ameli oration of the clinical phenotype of NDI. In the future, gene therapy approaches involving kidneyspecific deliv ery of wildtype AVPR2 or AQP2 could potentially cure congenital NDI.
